Copyright
©The Author(s) 2019.
World J Gastroenterol. Feb 28, 2019; 25(8): 989-1001
Published online Feb 28, 2019. doi: 10.3748/wjg.v25.i8.989
Published online Feb 28, 2019. doi: 10.3748/wjg.v25.i8.989
Figure 1 Difference in the anti-tumor necrosis factor alpha use rate (%) according to the diagnostic interval.
Anti-TNFα: Anti-tumor necrosis factor alpha.
Figure 2 Anti-tumor necrosis factor alpha-free survival between the early and delay groups according to the 24-mo diagnostic interval (P = 0.
034).
- Citation: Kang HS, Koo JS, Lee KM, Kim DB, Lee JM, Kim YJ, Yoon H, Jang HJ. Two-year delay in ulcerative colitis diagnosis is associated with anti-tumor necrosis factor alpha use. World J Gastroenterol 2019; 25(8): 989-1001
- URL: https://www.wjgnet.com/1007-9327/full/v25/i8/989.htm
- DOI: https://dx.doi.org/10.3748/wjg.v25.i8.989